Pulse Biosciences, Inc. announced a research collaboration with The University of Texas MD Anderson Cancer Center for treating thyroid tumors with nPulse™ technology.
The collaboration aims to assess the safety and effectiveness of using nPulse technology in treating thyroid cancers through a clinical study planned to start in 2026.
Preclinical studies are ongoing to evaluate the impact of nsPFA energy on anaplastic thyroid carcinoma, a deadly cancer type with a low survival rate.
IDE Approval
FDA approved the Investigational Device Exemption (IDE) for the clinical feasibility study of nPulse™ Vybrance™ Percutaneous Electrode System.
Nonthermal Mechanism
The nonthermal action of nsPFA technology may offer a scar-free and precise treatment for benign and malignant thyroid tumors.
Potential Benefits
nPulse technology could potentially benefit patients by sparing critical structures and minimizing damage during treatment.
- nPulse technology's non-thermal approach aims to limit scarring and fibrosis, showing promise in treating thyroid tumors.
- The collaboration with MD Anderson Cancer Center highlights the potential for nPulse technology to improve outcomes for patients with thyroid cancers.
Pulse Biosciences is pioneering innovative approaches to treat thyroid tumors with the nPulse technology, aiming to enhance patient care and outcomes in oncology. The research collaboration signifies a significant step towards advancing cancer treatment methods.